CURRENT AFFAIRS | 13 APRIL 2026
CLAT GK + LEGAL REASONING & HEALTH LAW
What Happened: Massive Counterfeit Cancer Drug Racket Exposed
A joint investigation by the Indian Express and the International Consortium of Investigative Journalists (ICIJ) has uncovered a sprawling counterfeit drug racket involving Merck’s Keytruda (pembrolizumab), one of the world’s most expensive and widely used cancer immunotherapy drugs costing approximately Rs 1.5 lakh per shot. The investigation revealed a sophisticated nexus of pharmacists, hospital staff, and fixers who exploited desperate cancer patients by selling fake versions of the life-saving drug using authentic batch numbers and recycled genuine vials.
The investigation tracked 11 distinct steps in the counterfeit supply chain, beginning inside oncology departments of major Delhi hospitals. Empty Keytruda vials were systematically collected by complicit hospital staff after administration to genuine patients. These used vials, bearing authentic batch numbers and barcodes, were then sold to middlemen who refilled them with unknown substances — potentially saline, expired drugs, or other inactive compounds — before resealing and reselling them on the black market at near-original prices to unsuspecting cancer patients.
The Enforcement Directorate (ED) has initiated a money laundering case under the Prevention of Money Laundering Act (PMLA) 2002 against the accused. Police have seized counterfeit vials matching batch numbers from multiple Delhi hospitals, confirming the institutional complicity in the fraud. This case raises fundamental questions about the right to health, pharmaceutical regulation, hospital accountability, and the adequacy of India’s drug safety framework.
Constitutional & Legal Framework
- Article 21 (Right to Life): The Supreme Court has consistently held that the Right to Life under Article 21 includes the Right to Health. In Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996), the Court ruled that the failure to provide timely medical treatment violates Article 21. Selling counterfeit drugs directly endangers this fundamental right.
- Drugs and Cosmetics Act, 1940: Section 17 defines misbranded drugs (false or misleading labels). Section 18 prohibits the manufacture, sale, or distribution of adulterated, spurious, or misbranded drugs. Violations attract stringent penalties including imprisonment.
- IPC Sections 274 & 275: Section 274 punishes adulteration of drugs (up to 6 months imprisonment). Section 275 punishes the sale of adulterated drugs. Under BNS (Bharatiya Nyaya Sanhita), equivalent provisions carry enhanced penalties.
- Consumer Protection Act, 2019: Replaced the 1986 Act. Introduces product liability provisions, making manufacturers, sellers, and service providers liable for defective goods or deficient services. The concept of unfair trade practice covers fraudulent drug sales.
- Prevention of Money Laundering Act (PMLA), 2002: Enables the ED to investigate and attach proceeds of crime. The ED can provisionally attach property within 180 days and prosecute for money laundering independently of the predicate offence.
- Parmanand Katara v. Union of India (1989): The Supreme Court held that every doctor has a professional obligation to provide medical aid to injured persons, establishing the duty of care in medical contexts.
Why This Matters for CLAT
This case is exceptionally important for CLAT preparation because it integrates multiple legal domains:
- Fundamental Rights in Action: CLAT frequently tests Article 21 expansions. The Right to Health, Right to Affordable Healthcare, and Right to Access Essential Medicines have all been read into Article 21 — this case provides a perfect factual matrix for such questions.
- Regulatory Framework Questions: The Drugs and Cosmetics Act 1940 is a core statute for CLAT GK. Understanding the difference between misbranded (Sec 17), adulterated (Sec 17A), and spurious drugs (Sec 17B) is essential.
- Hospital Liability & Vicarious Liability: Questions about whether a hospital is liable for the criminal acts of its staff (vicarious liability doctrine) test advanced legal reasoning skills.
- Consumer Protection: The 2019 Act’s product liability framework, central consumer protection authority, and unfair trade practice provisions are frequently tested in CLAT.
- PMLA & Financial Crime: Understanding money laundering investigations, the role of the ED, and the process of attachment and confiscation is increasingly tested in legal reasoning passages.
Key Facts at a Glance
| Drug Counterfeited | Keytruda (pembrolizumab) — Merck’s cancer immunotherapy drug |
| Cost Per Shot | Approximately Rs 1.5 lakh |
| Investigation By | Indian Express + ICIJ (International Consortium of Investigative Journalists) |
| Supply Chain Steps | 11 steps from hospital to black market |
| Key Constitutional Article | Article 21 — Right to Life includes Right to Health |
| Key Statute | Drugs and Cosmetics Act, 1940 (Sections 17, 18) |
| Investigating Agency | Enforcement Directorate (PMLA case) |
| Landmark Case | Parmanand Katara v. Union of India (1989) — Duty to provide medical aid |
| Consumer Protection | Consumer Protection Act 2019 — Product Liability provisions |
Mnemonic: FAKE DRUG
- F — Fundamental Right to Health (Article 21)
- A — Adulteration punished under IPC 274/275
- K — Keytruda (pembrolizumab) — immunotherapy drug
- E — Enforcement Directorate (PMLA case)
- D — Drugs & Cosmetics Act 1940
- R — Recycled vials with authentic batch numbers
- U — Unfair trade practice (Consumer Protection Act 2019)
- G — Guilty hospital staff — vicarious liability of hospitals
Test Your Knowledge
Practice Quiz — 10 CLAT-Style Questions
Click an option to reveal the answer and explanation.
